Development↦Management↦Study Approval↦Swissmedic
What is it? Why is it important?
Swissmedic is the Swiss authority responsible for licensing, authorization, and/or monitoring of therapeutic products, including:
- Human medicine
- Veterinary medicine
- Complementary & herbal medicine
- Medical devices
Core competencies include to:
- Approve clinical studies. In comparison to the Ethics Committee (EC) who approves studies of all risk-categories (i.e. A, B, and C), Swissmedic only approves studies with risk-categories B and C, such as:
- Medicinal Products (MP) studies with risk-category B and C (ClinO)
- Medical Devices (MD) studies with risk-category C (ClinO-MD) (i.e. these studies only have risk-categories A or C)
- Issue licences for the manufacturing of MPs
- Authorise MPs to be sold on the Swiss market
- Inspect studies to assess compliance with regulatory requirements and guidelines (e.g. Swiss Law, ICH GCP, ISO 14155)
- Monitor the safety and quality of MPs/MDs in studies and on the open market
- Inspect manufacturing companies to evaluate the quality of MPs/MDs
- Issue information aimed at healthcare professionals and patients
- Cooperate with national and international agencies
More
In comparison to MP authorisation requirements, MDs do not undergo official Swissmedic authorisation procedures. For MDs, Switzerland has adopted the EU system of compliance and assessment certification. Following the compliance assessmen, MDs are granted an CE label, which permits MDs to be placed / sold on the Swiss market.
Swissmedic is attached to the Federal Department of Home Affairs.
What do I need to do?
As a SP-INV with a risk-category B or C study, submit an application dossier for approval to Swissmedic over the Swissmedic application portal.
Submission can be done concurrently with the EC submission. EC submission is required for all studies irrespective of the risk-category of the study.
As a SP-INV keep in mind to notify to Swissmedic any:
- Changes to the conduct if your study (e.g. amendments)
- Changes to the ongoing risk-benefit evaluation
- Other reporting obligations (e.g. first-patient-in, safety reporting, annual safety report, study completion, and clinical study report)
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
External Links
Swissmedic - see in particular
- Human medicines / Clinical trials
- Medical devices / Clinical trials
References
ICH GCP E6(R2) – see in particular article
- Art. 1.49 Definition regulatory authorities
KOFAM: Coordination portal for human research – see in particular
- Online wizard for risk categorisation
Swiss Law
ClinO – see in particular articles and annex
- Art. 23 Coordination and information in authorisation procedures
- Art. 30-34 Swissmedic Submission, Timelines and Approval Process including Studies with Radiation Source
- Annex 4 Application documents to swissmedic